RxDoctor Payments Data

David Pimentel, MD

Cardiovascular Disease · Norwood, MANPI 1396722203

Payments from drug & device makers

$316,573in general payments, 2019–2025

Across 31 payments — averaging $10,212 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$316K
  • Covidien LP$138
  • Boehringer Ingelheim$30
  • Bardy Diagnostics, Inc.$20

What the payments were for

  • Speaking & faculty fees$2557%
  • Travel & lodging$2,64275%
  • Food & beverage$64518%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly28$316,385
Covidien LP1$138
Boehringer Ingelheim1$30
Bardy Diagnostics, Inc.1$20

How this compares

$316,573 in reported general payments places this provider in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$58,739
Medicare patients
171
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$220,982
JardianceEmpagliflozin218$183,016
EntrestoSacubitril/Valsartan141$147,326
EliquisApixaban99$87,434
FarxigaDapagliflozin Propanediol43$36,797
XareltoRivaroxaban29$30,053
InvokanaCanagliflozin11$6,430
Metoprolol Succinate302$5,174
Torsemide145$4,575
Humalog Kwikpen U-100Insulin Lispro11$3,309
Atorvastatin Calcium241$3,266
Eplerenone24$2,440
Carvedilol129$1,851
Potassium Chloride54$1,627
Spironolactone151$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$183,016218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Norwood

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →